Infliximab in the therapy of rheumatoid arthritis

• Main Authors: G. V. Lukina, Y. A. Sigidin, E. S. Posdnyakova, E. L. Luchihina, D. E. Karateev, E. L. Nasonov
• Format: Article
• Language: Russian
• Published: IMA-PRESS LLC 2016-05-01
• Series: Научно-практическая ревматология
• Subjects: rheumatoid arthritis; anticytokine therapy; infliximab
• Online Access: https://rsp.mediar-press.net/rsp/article/view/2189

Objective. To assess efficacy and tolerability of infliximab in pts with rheumatoid arthritis (RA) in real clinical practice.Materials and methods. 75 RA pts with high disease activity according to DAS 28 in 80% who received previous antirheumatic drugs without proper effect were included in an open clinical trial. DAS 28 and ACR criteria were used as primary outcome measures.Results. Infliximab administration provided significant clinical improvement in most pts. Already in a week after the first infusion 20% ACR improvement was achieved in 74% of pts. Significant improvement of all the main treatment effect parameters was achieved after the second infusion. ESR and CRP mean values normalized after the third infusion. Rheumatoid factor decrease was noted after 6 weeks. Mean values of tender and swollen joint counts significantly decreased but arthritis signs remained in a part of pts. Clinical remission was achieved in 4 (19%) from 21 pts completed a year’s course of treatment and in 4 pts the treatment was not effective. Serious adverse events requiring infliximab withdrawal (including infectious arthritis, hand phlegmon and bronchitis) appeared in 7 ptsConclusion. These results show high efficacy of infliximab and prove advisability of its administration in RA